Twist Bioscience CORP Form 4 insider transactions

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, reported sales of company common stock totaling 7,175 shares in early February 2026.

Twist Bioscience SVP of Human Resources, Paula Green, sold 1,194 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Twist Bioscience's President and COO, Patrick John Finn, sold 2,390 shares of common stock at $44.908 per share to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 3,000 shares of common stock for $40 per share under a pre-arranged 10b5-1 trading plan.

Patrick John Finn, President and COO of Twist Bioscience Corp., executed a pre-arranged plan to exercise stock options and sell 23,279 shares of common stock.

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 2,738 shares of common stock at $35.261 per share to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience's SVP of Human Resources, Paula Green, sold 273 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Dennis Cho, SVP and Chief Legal Officer of Twist Bioscience, sold 324 shares of common stock to cover tax withholding obligations related to RSU vesting.

Twist Bioscience CEO Emily M. Leproust sold 1,605 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

A Twist Bioscience executive sold 398 shares of common stock at $32.878 per share to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience CEO Emily M. Leproust sold 2,255 shares of common stock at $32.878 per share to cover tax withholding obligations related to vested Restricted Stock Units.

Twist Bioscience's SVP of Human Resources, Paula Green, sold 877 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 230 shares of common stock to cover tax withholding obligations related to RSU vesting.

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Twist Bioscience's Chief Legal Officer, Dennis Cho, sold 757 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience's President and COO, Patrick John Finn, sold 1,776 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.

Twist Bioscience's SVP of Human Resources, Paula Green, sold 598 shares of common stock to cover tax withholding obligations related to RSU vesting.

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 887 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience CEO Emily M. Leproust sold 2,663 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.

Twist Bioscience Corp. has granted its Senior Vice President, Chief Legal Officer & Corporate Secretary, Dennis Cho, 25,465 restricted stock units.

Twist Bioscience Corp's SVP of Human Resources, Paula Green, was granted 26,200 restricted stock units, vesting quarterly over four years.

Twist Bioscience Director Jan Johannessen reported the sale of 7,044 shares of common stock at $24.77 per share.

Twist Bioscience CEO Emily M. Leproust received an award of 146,914 restricted stock units, vesting over 48 months.

Patrick John Finn, President and COO of Twist Bioscience Corp, received a restricted stock unit award of 68,740 shares.

Twist Bioscience's Chief Financial Officer, Adam Laponis, was granted 32,648 restricted stock units, vesting quarterly over four years.

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, was granted 16,324 restricted stock units, increasing his beneficial ownership to 67,194 shares.

Twist Bioscience's Chief Legal Officer, Dennis Cho, sold 1,019 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience's President and COO, Patrick John Finn, sold 2,755 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Twist Bioscience's SVP of Human Resources, Paula Green, sold 1,084 shares of common stock to cover tax withholding obligations related to RSU vesting.

Twist Bioscience CEO Emily M. Leproust sold 4,887 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.